Amgen Mum On Repatha Sales; Outcomes Data Needed To Sway US Payers
This article was originally published in Scrip
Amgen Inc.'s 2015 revenue of $21.66bn, up 8% from the prior year, met analyst consensus expectations, but one of the biggest questions of all was left unanswered: How many millions of dollars in sales of the PCSK9 inhibitor Repatha (evolocumab) has the company generated so far?
You may also be interested in...
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.